Actively Recruiting
Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics
Led by Massachusetts General Hospital · Updated on 2025-06-12
80
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the use of intermittent theta-burst transcranial magnetic stimulation (iTBS-TMS) targeting the inferior parietal lobule (IPL) to reduce suicide risk in adults diagnosed with major depressive episode (MDE) or borderline personality disorder (BPD). This neuroimaging clinical trial also aims to identify brain circuit features linked to suicidal behavior and to understand biological predictors and mechanisms of response to this treatment. Participants are randomly assigned to one of four groups: those with MDE or BPD receiving active iTBS-TMS, and those with MDE or BPD receiving a sham (inactive) version of iTBS-TMS. The active treatment uses a magnetic device to stimulate specific brain areas, while the sham procedure mimics the sensation without actual brain stimulation. Treatments are delivered using a specialized device over the target brain region. During the study, participants undergo neuroimaging scans and assessments to monitor changes in brain connectivity related to treatment response. The primary outcome measured is the change in functional connectivity of key brain nodes, assessed throughout the treatment period averaging three days. Researchers also evaluate clinical severity of suicidal risk and monitor participants for safety, with the entire involvement lasting through treatment completion and follow-up as planned.
CONDITIONS
Brief Title
Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 to 65 years of age
- Diagnosed with borderline personality disorder or major depressive episode
- Chief complaint of suicidal thoughts and behaviors
You will not qualify if you...
- Neurological conditions with known structural brain lesion
- Prior neurosurgical procedure
- Presence of ferromagnetic metal in the body or metal injury to the eyes
- Epilepsy
- Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit, or ventriculo-peritoneal shunt
- Psychopathology not appropriate for treatment (e.g., manic episode or psychosis)
- Current alcohol dependence or active symptoms of non-alcohol psychoactive substance withdrawal
- Inability to meet safety criteria for MRI scanning
- Current pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 3 days
Participants receive intermittent theta burst transcranial magnetic stimulation (iTBS-TMS) or sham treatment targeting specific brain regions.
3 treatment visits (in-person)
Trial Site Locations
Total: 1 location
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02129
Actively Recruiting
Research Team
D
DNN Inbox
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here